Immunicum starts enrolment in US for Phase II oncology trial
Swedish biopharmaceutical firm Immunicum has started patient enrolment in the US for the ongoing Phase II MERECA clinical trial of its drug candidate ilixadencel to treat renal cell carcinoma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Carcinoma | Clinical Trials | Kidney Cancer | Pharmaceuticals | Renal Cell Carcinoma | Sweden Health